Last Updated : October 17, 2024
Details
Generic Name:
pembrolizumab
Project Status:
Pending
Therapeutic Area:
advanced or metastatic malignant pleural mesothelioma (MPM)
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0387-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Keytruda in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult and pediatric (12 years and older) patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Fee Schedule:
Pending
Indications:
Keytruda in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult and pediatric (12 years and older) patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : October 17, 2024